Építés alatt – nem éles oldal
Belépés
Csak meghívásosFázis nélkül

ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

A legfontosabb adatok

Ki végzi
Abbott Medical Devices
Hol
Montreal, Ottawa, Saint John, Toronto és Vancouver (Kanada)Mind a 6 helyszín megnézéseMég 12 másik országban, 101 helyszínen
Azonosító
Állapot
Csak meghívásos
Résztvevők
1500 fő, tervezett
Kezdés
2024. márc. 15.
Várható befejezés
2036. ápr.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Navitor Transcatheter Aortic Valve Implantation (TAVI) System
  • Any Commercially Available Transcatheter Aortic Valve (CAV) System
A regiszteradat frissítve
2026. szeptember 11.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with severe aortic stenosis that causes symptoms. In the main group, people have low or intermediate risk from open heart surgery. Other groups include people whose earlier replacement valve is failing, and people with a bicuspid (two-leaflet) aortic valve.

Életkor
18 Years and older
Nem
All
A betegség stádiuma
Severe, symptomatic, degenerative aortic valve stenosis. Heart failure symptoms of NYHA class II, III or IV. Main group: estimated surgical death risk < 3% (low) or ≥ 3% and < 8% (intermediate) at 30 days.
Korábbi kezelés
Main group: no earlier artificial heart valve or other valve implant. Valve-in-valve group: a failing surgical or catheter-placed biological aortic valve. No heart artery or blood vessel procedure through the skin within 30 days before, except pacemaker or ICD.

A részvétel fő kizáró okai

  • Expected to live less than 2 years (less than 1 year in the bicuspid group)
  • Heart attack within 30 days, or stroke or TIA within 6 months
  • Kidney failure (creatinine > 3.0 mg/dL (265 µmol/L) or eGFR < 30 ml/min/1.73m2) or needing chronic dialysis
  • Weak heart pumping with LVEF < 30%
  • Severe mitral valve leak or narrowing, or untreated coronary artery disease needing a procedure

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Ki vehet részt

  • Subject who is deemed to be at intermediate or low risk for open surgical aortic valve replacement:; Intermediate risk: estimated risk of overall surgical mortality ≥ 3% and < 8% at 30 days; Low risk: estimated risk of overall surgical mortality < 3% at 30 days Estimated risk of overall surgical mortality includes consideration of the Society of Thoracic Surgeons (STS) risk score, overall clinical status, and other clinical co-morbidities unmeasured by the risk calculator
  • New York Heart Association (NYHA) Functional Classification of II, III, or IV
  • Degenerative aortic valve stenosis

Ki nem vehet részt

  • Evidence of an acute myocardial infarction [defined as ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) with acute ischemia symptoms and troponin elevation] within 30 days prior to index procedure
  • Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior (except pacemaker or implantable cardioverter defibrillator (ICD) implant) to index procedure or planned within 30 days following the index procedure
  • Active peptic ulcer or upper GI bleeding within 3 months prior to index procedure that would preclude anticoagulation
  • Recent (within 6 months prior to index procedure date) cerebrovascular accident (CVA) or a transient ischemic attack (TIA)
  • Hostile chest or conditions or complications from prior surgery that would make the subject be considered high surgical risk (i.e., mediastinitis, radiation damage, abnormal chest wall, porcelain aorta, adhesion of aorta or internal mammary artery to sternum, etc.)
  • Hostile Chest or conditions or complications from prior surgery that would make the subject be considered high surgical risk
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Significant frailty as determined by the heart team (after objective assessment of frailty parameters) that would indicate high or extreme surgical risk
  • Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation 3-4+)
  • Pre-existing prosthetic heart valve or other implant (such as prosthetic ring or transcatheter edge-to-edge repair (TEER) clip) in any valve position
  • Significant frailty as determined by the heart team (after objective assessment of frailty parameters) that would indicate high or extreme surgical risk
  • Mixed aortic valve disease
  • Pre-existing prosthetic heart valve or other implant (such as prosthetic ring or transcatheter edge-to-edge repair (TEER) clip) in any valve position; Additional Exclusion Criteria for ViV Cohort
  • Patient has a pre-existing prosthetic heart valve or other implant (such a prosthetic ring with a rigid support structure or transcatheter edge-to-edge repair clip) in any valve position other than aortic
  • Blood dyscrasias as defined: leukopenia (WBC < 3000 mm3), acute anemia (Hb < 9 g/dL), thrombocytopenia (platelet count < 50,000 cells/mm³); history of bleeding diathesis or coagulopathy
  • Renal insufficiency (creatinine > 3.0 mg/dL or eGFR < 30 ml/min/1.73m2) and/or end stage renal disease requiring chronic dialysis
  • Severe ventricular dysfunction with LVEF < 30% as measured by resting echocardiogram
  • Severe circumferential mitral annular calcification (MAC) which is continuous with calcium in the left ventricular outflow tract (LVOT)
  • In the opinion of the Investigator, life expectancy is less than 2 years
  • Aortic valve is a unicuspid or bicuspid valve as verified by echocardiography or CT
  • Severe (greater than or equal to 3+) mitral regurgitation or severe mitral stenosis
  • Minimum access vessel diameter of < 5.0 mm for small FlexNav Delivery System and < 5.5 mm for large FlexNav Delivery System
  • Eccentricity ratio of the annulus < 0.73; Additional Exclusion Criteria for Pivotal Randomized Cohort
  • Aortic valve is a unicuspid or bicuspid valve as verified by echocardiography or CT
  • Inadequate aortic valve calcification
  • Failing valve has moderate or greater paravalvular regurgitation
  • Known severe prosthesis-patient mismatch
  • Failing valve is unstable, rocking, or not structurally intact
  • Bioprosthetic valve diameter that would not accommodate implantation of the Navitor Valve
  • Increased risk of coronary obstruction by prosthetic leaflets of the index valve; Additional Exclusion Criteria for bicuspid cohort
  • In the opinion of the Investigator life expectancy is less than 1 year
  • Inadequate or severe aortic valve calcification and/or anatomical features that would preclude safe delivery of the valve

Helyszínek itt: Kanada

Még 12 másik országban, 101 helyszínen

  • Institut de Cardiologie de Montreal (Montreal Heart Inst.)Montreal, KanadaCsak meghívásos
  • MUHC - The Royal Victoria HospitalMontreal, KanadaCsak meghívásos
  • University of Ottawa Heart InstituteOttawa, KanadaCsak meghívásos
  • Saint John Regional Hospital - New Brunswick Heart CentreSaint John, KanadaCsak meghívásos
  • St. Michael's HospitalToronto, KanadaCsak meghívásos
  • St. Paul's HospitalVancouver, KanadaCsak meghívásos

A vizsgálatról

Mit akar kideríteni a vizsgálat

The objective of ENVISION is to evaluate the safety and effectiveness of the Navitor Transcatheter Aortic Valve Implantation (TAVI) System for treating patients with symptomatic, severe native aortic stenosis who are considered intermediate or low risk for surgical mortality.

A teljes eredeti leírásKevesebb

The trial will also evaluate the safety and effectiveness of the Navitor TAVI System in a valve-in-valve (ViV) application in patients with symptomatic heart disease due to failure of a surgical or transcatheter bioprosthetic aortic valve who are at high or greater surgical risk.

In addition, the trial will assess the safety of the Navitor TAVI System for the treatment of symptomatic, severe native aortic stenosis in patients with bicuspid aortic valve anatomy, irrespective of surgical risk classification.

A vizsgálat 2 csoportja

  • Navitor Transcatheter Aortic Valve Implantation (TAVI) SystemA vizsgált kezelés

    TAVI with Abbott Navitor Transcatheter Aortic Valve Implantation (TAVI) System

  • Any Commercially Available Transcatheter Aortic Valve System (CAV)Már használt kezelés, összehasonlításként

    TAVI with any FDA approved commercially available Transcatheter Aortic Valve System (CAV)

    Kezelés: Any Commercially Available Transcatheter Aortic Valve (CAV) System

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Evaluation of the Navitor Transcatheter Heart Valve in Low and Intermediate Risk Patients Who Have Severe, Symptomatic, Aortic Stenosis Requiring Aortic Valve Replacement
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2026. szeptember 11.